1
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Silodosin in the treatment of benign prostatic hyperplasia

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Benign prostatic hyperplasia (BPH)-associated lower urinary tract symptoms (LUTS) are highly prevalent in older men. Medical therapy is the first-line treatment for LUTS due to BPH. Alpha-adrenergic receptor blockers remain one of the mainstays in the treatment of male LUTS and clinical BPH. They exhibit early onset of efficacy with regard to both symptoms and flow rate improvement, and this is clearly demonstrated in placebo-controlled trials with extensions out to five years. These agents have been shown to prevent symptomatic progression of the disease. The aim of this article is to offer a critical review of the current literature on silodosin, formerly known as KMD-3213, a novel alpha-blocker with unprecedented selectivity for α 1A-adrenergic receptors, as compared with both α 1B- and α 1D -adrenoceptors, exceeding the selectivity of all currently used α 1-blockers, and with clinically promising effects.

          Related collections

          Author and article information

          Journal
          Drug Des Devel Ther
          Drug Design, Development and Therapy
          Drug Design, Development and Therapy
          Dove Medical Press
          1177-8881
          2010
          27 October 2010
          : 4
          : 291-297
          Affiliations
          Department of Urology, Erasme Hospital, University Clinics of Brussels, ULB, Brussels, Belgium
          Author notes
          Correspondence: Thierry Roumeguère, Department of Urology, Erasme Hospital, University Clinics of Brussels, ULB, Route de Lennik, 808, 1070 Brussels, Belgium, Tel +32 2555 3614, Fax +32 2555 3614, Email thierry.roumeguere@ 123456erasme.ulb.ac.be
          Article
          dddt-4-291
          10.2147/DDDT.S10428
          2990389
          21116335
          © 2010 Rossi and Roumeguère, publisher and licensee Dove Medical Press Ltd.

          This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.

          Categories
          Review

          Comments

          Comment on this article